7/102 sources · 2 publishersUpdated Oct 8, 22:25 UTC
Novartis pays $575 million upfront for Abogen mRNA autoimmune program
On Oct 6, Novartis announced an upfront payment of $575 million to Abogen for the ABO2203 mRNA program aimed at autoimmune diseases. The agreement could rise to $7.8 billion if development milestones are achieved, with the upfront representing about 7.4% of the total potential value. Novartis shares ticked up 0.1% to $141.035 after the news.
Why it matters
The deal expands Novartis's pipeline in the autoimmune space, but investors face risk that future milestone payments depend on clinical success and regulatory approval.
Key facts
- 1Novartis shares rose 0.1% to $141.035 on Oct 6. gurufocus.com
- 2Novartis made an upfront payment of $575 million to Abogen for the ABO2203 program. gurufocus.com
- 3The total potential deal value could reach $7.8 billion if milestones are met. gurufocus.com
- 4The upfront payment represents 7.4% of the maximum deal value. finance.yahoo.com
- 5ABO2203 is an mRNA program targeting autoimmune diseases. gurufocus.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.